depression glp 1 Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine GLP-1 Drugs Reduce Depression, Boost

However, certain elements, such as existing CVDs or CKD, could affect how GLP-1 responds

Therefore, treatment approaches in these patients depend on various clinical factors, including presence of the symptoms, possibility of significant structural disease progression, disease localization, disease volume or burden, and location of the metastatic lesion [1,4,6]

The glucagon component can also cause transient increases in heart rate and blood glucose, effects that do not occur with amylin-based compounds

Cold Spring Harbor Perspect Biol 14(3):a041012 Funding Open access publishing supported by the institutions participating in the CzechELib Transformative Agreement

10.1186/s12918-016-0307-y 176 YanceyP